Academic Medical Center (AMC)
Meibergdreef 9
1105 AZ Amsterdam
Website Academic Medical Center
E-mail Amsterdam Medical Center
T +31 (0)20 566 50 56
F +31 (0)20 566 91 68

Employees in Amsterdam: 6,500
Employees in R&D: 1,400
Year of foundation: 1983

Company Profile

Science and Technologies or Services

AMC is active in the following research fields:

• Cardiovascular Diseases
• Gastr-intestinal diseases
• Immunity and Infections
• Metabolic Disorders
• Neurologic and Psychiatric Disorders
• Oncology
• Public Health and Epidemiology

AMC also offers advanced facilities and highly qualified personnel in the areas of gene and cell therapies, viral vector production, genomics, proteomics, metabolomics, bioinformatics, imaging, and animal models.

Alliances

AMC spin-offs:

• AIMM Therapeutics
• AMCAS
• Amsterdam Molecular Therapeutics (AMT)
• Arthrogen
• Hep-Art Medical Devices
• IATEC
• Macrozyme
• MicroVision Medical
• Primagen
• Valletta Health

Keywords

• Academic hospital
• Medical research
• License opportunities
• Spin-off companies
  

AIMM Therapeutics B.V.
Meibergdreef 45
1105 BA Amsterdam
Website AIMM Therapeutics B.V.
E-mail AIMM Terapeutics B.V.
T +31 (0)20 566 26 48
F +31 (0)20 566 91 58

Employees in Amsterdam: 5
Employees in R&D: 5
Year of foundation: 2005

Company Profile

AIMM’s portfolio is based on proprietary platform technologies for directed, fast and efficient development of fully human monoclonal antibodies. Many innovative products for a wide range of viral and bacterial diseases as well as for cancer, are being developed.

Science and Technologies or Services

The goal is to isolate antibody-producing B cells from humans that have resolved a pathogenic challenge with high or exceptional efficiency. This would allow for the direct isolation of monoclonal antibodies with proven effectiveness in a clinical setting. Such proprietary B cell immortalization technologies for the selective isolation of human B cells shall lead to antibodies with desirable specificities.

Alliances

• AMC-Amsterdam;
• UMCU-Utrecht;
• NVI-Bilthoven.

Keywords

• Human antibodies;
• Vaccines.

AM-Pharma B.V.
Rumpsterweg 6
3981 AK Bunnik
Website AM-Pharma B.V.
E-mail AM-pharma B.V.
T +31 (0)30 228 92 22
F +31 (0)30 228 92 20

Employees in Amsterdam: 17
Employees in R&D: 17
Year of foundation: 2000

Company Profile

AM-Pharma is a biopharmaceutical company, based in Bunnik, The Netherlands. The company is focused on the pre-clinical and clinical development of novel therapeutics to treat inflammatory diseases and infectious diseases. All our products address high medical needs and commercially attractive markets.
Our products are based on endogenous proteins and (protein derived) peptides, optimised to fight inflammatory diseases and infections. AM-Pharma has intellectual property around two scientific platforms:

• Enhancing Toll Like Receptor mediated activation of innate immune cells
• Dephosphorylation of extracellular substrates to influence disease processes

So far, AM-Pharma has developed two products originating from its intellectual property franchise, Alkaline Phosphatase and hLF1-11 up to the point of initial proof of clinical efficacy and safety.
AM-Pharma currently employs 17 people. We out-source all non-core know how dependent development work to specialist third party organisations.
Once our products have shown to be safe and effective in patients we out-license our products to collaboration partners who become responsible for further development and worldwide marketing.

Science and Technologies or Services

Alkaline Phosphatase (AP) (acute renal failure and ulcerative colitis)
The endogenous enzyme alkaline phosphatase is expressed in various tissues throughout the human body including kidney and GI tract. AP has been shown to dephosphorylate LPS to a non-toxic form that acts as a partial antagonist on the LPS receptor complex. In addition to LPS, AP can dephosphorylate different other substrates e.g. ATP and through this dephosphorylation interfere with inflammatory response and associated tissue damage. Proof of concept has been shown in Phase IIa Proof Of Concept trials in Acute Renal Failure and Ulcerative Colitis.

HLF 1-11 Anti microbial peptide
The antimicrobial peptide hLF1-11 comprises the first 11 N-terminal amino acids of the endogenous protein; human lactoferrin. The compound exerts both antibacterial and antifungal activity against a broad range of microorganisms. Moreover, it appears that hLF1-11 has a low propensity to generate resistance in microorganisms, because it acts by stimulating the innate immune system. Phase IIa Proof Of Concept trials have are in preparation in MRSA infections and systemic Candida infections.

Keywords

• Acute Renal Failure
• Ulcerative Colitis
• MRSA
• Systemic candida infection
• Phase II clinical development
• Anti-infective
• Anti-inflammatory
  

Piet Heinkade 183
1019 HC Amsterdam
Website
E-mail
T +31 (0)88 650 6500
F +31 (0)88 650 6555

Employees: 3
Employees in R&D: 0
Year of foundation: 2011

Company Profile

We focus entirely on the life sciences, together we have over 20 years of experience in the life science sector both as attorney at law and as in-house counsel.

Keywords

• law
• legal services
• coaching of high tech and life sciences start-up and spin-out companies

Zernikedreef 11
2333 CK Leiden
Website
E-mail
T +31 (0)71 518 8743
F +31 (0)71 518 8415

Employees: 6
Employees in R&D: 0
Year of foundation: 2007

Company Profile

CBD is a non-profit organization staffed by a small, dedicated group of lecturers affiliated to the Faculty of Technology in the University of Applied Sciences Leiden (Hogeschool Leiden). We possess a track record in successful postgraduate education of technical lab personnel, spanning over 20 years. Our main focus is to strengthen and modernize the theoretical and practical knowledge base of technical personnel involved in laboratory work in health care, pharmaceutical, industrial and forensic settings, thereby providing a secure basis for quality improvement. We also provide consultancy services for clients seeking to optimize lab tests and boost their quality assurance procedures.
Organisations who chose CBD for their schooling and training needs include VUmc, Crucell, Philips Healthcare Incubator, UMC Groningen, Naktuinbouw, Radboud University Medical Center, Vitens, Erasmus Medical Center and Heineken.

Science and Technologies or Services

CBD is active in the following areas of life science training and consultancy:

• Molecular biology/molecular diagnostics
• Microbiology/infectious diseases
• Immunology and immunochemistry
• Clinical chemistry and hematology
• Histology/pathology
• Agriculture/horticulture

CBD offers

• training courses for groups or individuals (at the University of Applied Sciences Leiden)
• incompany training trajectories, in which the course content is tailored to fit the schooling and quality improvement needs of the client
• consultancy services
• organization of conferences.

Alliances

• Toplab @ Hogeschool Leiden
• Naktuinbouw
• Boerhaave Nascholing, LUMC
• Symbiant

Keywords

• University of Applied Sciences Leiden
• life sciences
• postgraduate professional education
• in company training
• consultancy
• molecular biology/ molecular diagnostics
• microbiology/ infectious diseases
• immunology and immunochemistry
• clinical chemistry and hematology
• histology / pathology
• agriculture / horticulture

Clinical Reach Drug Development b.v.
Zoeterwoudseweg 74
2321 GP Leiden
Website Clinical Reach
E-mail Clinical Reach
T +31 (0)71 531 18 52

Employees in Amsterdam: 1
Employees in R&D: 1
Year of foundation: 2009 

Company Profile

Clinical Reach is an independent company that aims to be a partner in your development team, from the strategic level down to the level of hands-on support in the execution of individual studies.

Company Profile

We join you in your goal to develop a product that meets regulatory expectations and that will be commercially successful. Pending your needs, we support you in your efforts to:

• Define the target product profile. 
•  Define the development plan that brings you to that target. 
•  Seek key opinion leader and regulatory authority challenge of the target product profile and development plan. 
•  Design the individual studies in your development plan. 
•  Identify the appropriate contract research organization to execute your studies, and work with this external partner on a day-to-day basis until the study has been reported. 
•  Present your plans and data to external parties, including investors, potential licensing partners and regulatory agencies.

Alliances

We are informally associated with various expert companies and individual experts providing services complementary to those of Clinical Reach, including:

• Regulatory services. 
•  Pharmaceutical development and clinical trial material production, packaging and labeling.
• Clinical study execution and management services. 
•  Recording and reporting of electronic patient-reported outcome (ePRO) data. 
•  Bioanalytical services, including biomarker assays and immunogenicity assessments. 
•  Pharmacokinetic and –dynamic data analysis. 
•  Modeling and simulation from clinical trial design to kinetic and dynamic data. 
•  Data management and statistics. 
•  Medical writing.

Keywords

• Target product profile
• drug development
• regulatory challenge
• key opinion leader challenge
• study design and execution
  

DC4U B.V.
Van der Boechorststraat 7
1081 BT Amsterdam
E-mail DC4U B.V.
T +31 (0)20 444 80 84
F +31 (0)20 444 80 81

Year of foundation: 2006

Company Profile

Science and Technologies or Services

Recently, glycomics research has yielded potential leads that may provide innovative solutions for the treatment of cancer. Glycomics is a new biomedical discipline that investigates how sugar modification of macromolecules (glycosylation) affects their biological and pathological function. Recent exciting discoveries in this field, in which Prof. Dr. Y. van Kooyk has a world-leading role, are further explored. DC4U B.V. strongly believes that liposomes containing highly specific APC-targeting signals using glycans provide the answer in the search for a new vaccine to cure colon cancer. The fact that certain glycans can target two different APC subsets allows us for the first time to design a vaccine that targets both subsets that have strong immune-modulating capacity.

Alliances

• Drug Discovery Factory B.V.
• VU Medical Center Amsterdam
• Octoplus Technologies B.V.
• Utrecht University
• Technical University Munchen

Keywords

• Cancer
• Therapeutics
• Vaccines
• Immunotherapy
• Autoimmunity
• Dendritic Cells
• Drug Discovery

Drug Discovery Factory BV
Albrechtlaan 14a
1404 AK Bussum
Website Drug Discovery Factory B.V.
E-mail Drug Discovery Factory B.V.
T +31 (0)35 695 40 50

Employees in Amsterdam: 14
Employees in R&D: 10
Year of foundation: 2003

Company profile

Currently the DDF group consists of 12 companies in the life sciences Using a hands-on approach and dedication to meet customer demands we aim to create value for our clients and other stakeholders. Peter Schoevers and Henk Viëtor, the founders of DDF, have established themselves as two of the leading Life Sciences entrepreneurs behind successful companies such as Recharge, DCPrime, Skyline Diagnostics, Dynomics and Julius Clinical Research.

Science and Technologies or Services

Selecting
DDF selects the most attractive research projects at leading University Medical Center and other research institutions.

Financing
DDF provides and/or organizes funding and grants.

Managing
DDF monitors the projects, files patents, finds partners, provides (project) management.

Commercialising
DDF markets and sells projects, products and services.

Consulting
The team of 14 employees of DDF undertakes management activities, consultancy activities, IP management and financial administration activities.

Alliances

We have a dedicated network of partners to realize research and development projects and work closely with academic hospitals, regulatory authorities and local and national governments.

Keywords

• Drug development;
• University;
• Intellectual property;
• Consultancy;
• Entrepreneurship;
• Commercialisation.

Schutteheiweg 37
6343AG Klimmen
Website
e-mail
T +31 (0)6 5460 7087

Employees: 1
Year of foundation: 2008

Company Profile

Science and Technologies or Services

Alliances

Keywords

Genmab B.V.
Yalelaan 60
3508 AD Utrecht
Website Genmab B.V.
T +31 (0)30 212 31 23
F +31 (0)30 212 31 10

Employees in Amsterdam: 130
Employees in R&D: 130
Year of foundation: 2001

Company Profile

Science and Technologies or Services

Genmab uses a combination of innovative technology platforms in multidisciplinary teams of biologists, biochemists and MD's. Antibodies, one of the body’s most important natural defenses, are proteins that seek out, recognize and bind to disease targets. A specific antibody directs the immune system to a particular target like a key fitting into a lock. It is this specificity that makes antibodies potentially useful in various therapeutic applications. Our skilled pre-clinical team, located in Utrecht, ensures that the best possible antibody candidate is selected to become a potential product. A panel of antibodies is generated and these antibodies are put through a rigorous series of laboratory functional assays designed to identify characteristics of the best therapeutic product.

Alliances

Keywords

• Genmab;
• Biotech;
• Human antibodies;
• Monoclonal antibodies;
• Drug discovery;
• Drug development;
• Pre-clinical;
• Oncology;
• Inflammatory diseases;
• Infectious diseases.

Genzyme Nederland
Gooimeer 10
1411 DD Naarden
Website Genzyme Nederland
E-mail Genzyme Nederland
Promotion video Genzyme Nederland
T +31 (0)35 699 86 00
F +31 (0)35 699 86 21

Employees in Amsterdam: 415
Employees in R&D: 150
Year of foundation: 1991

Company Profile

Science and Technologies or Services

Genzyme’s research and development efforts are focused on the areas of medicine where it markets commercial products. The company also conducts research in cardiovascular disease and other areas of unmet medical need. In 2006, the company invested approximately $565 million in this work, or about 18 percent of its revenues. Genzyme identifies unmet medical needs and its large team of scientists and researchers uses a broad range of scientific approaches and technologies to meet those needs. The company is a leader in novel areas such as cell and gene therapies and biomaterials. Genzyme also partners with other companies to develop new products and supports research conducted by top academic and independent medical science centers.

Alliances

Genzyme has many different alliances with companies and research groups around the world. In the Netherlands Genzyme is collaborating with Macrozyme BV in the area of diabetes and scientific and clinical projects are ongoing with researchers in several academic centers, including the AMC.

Keywords

• Orphan diseases
• Renal disease
• Oncology
• Transplant
• Orthopedics
• Familial Hypercholesterolemia
  
  

Greenberg Traurig LLP
Strawinkskylaan 3127
1077 ZX Amsterdam
Website
E-mail
T +31 20 301 7436
F +31 20 301 7350

Employees: 100
Employees in R&D: 60
Year of foundation: 2003

Company Profile

Greenberg Traurig is a law firm of 1800 lawyers in more than 30 locations focused on helping businesses navigate change in every way. Through its offices in the US, Europe and Asia it has a global reach yet local footprint.

Science and Technologies or Services

GT provides world-class and worldwide industry-oriented life sciences legal services in all areas of law, including IP, licensing, M&A, regulatory compliance, litigation, etc.

Alliances

Through its alliance partners GT can provide legal services in markets where it is not established itself, enabling GT to provide legal services in every country in the world.

Keywords

• Legal
• Regulatory
• M&A
• Contracts
• Litigation

Holland Health Comeniusstraat 10 1817 MS Alkmaar Website Holland Health E-mail Holland Health T +31 (0)72 519 57 74 F +31 (0)72 519 58 77 Employees in Amsterdam: 1 Employees in R&D: 1 Year of foundation: 2008

Company profile

Medical cluster foundation which stimulates health care

Science and Technologies or Services

Supports science en technology innovation by knowledge and venture capital

Alliances

• Ontwikkelingsbedrijf Noord-Holland Noord;
• Medical Center Alkmaar;
• Tromp Medical;
• Kamer van Koophandel;
• Boehringer Ingelheim;
• H&S Adviesgroep;
• NRG Petten.

Keywords

• Medical innovation

Jozef Israëlskade 46
1072 SB Amsterdam
Website
E-mail
T +31(0)20 570 02 00
F +31(0)20 676 44 78

Employees: 160
Employees in R&D: 0
Year of foundation: 1973

Company Profile

HORLINGS Accountants and Tax Consultants is a professional services firm employing over 160 professionals in Amsterdam, Heemstede and Hoofddorp. Our Amsterdam team of consultants specializes in international (tax) advice for corporates and (their) employees. We have a firm and well-known experience in providing full service to our clients and are able to respond swift and accurate to all your questions and queries.
At Horlings we continuously challenge each other to improve our performance even further. We closely follow every new development in our chosen area of expertise as well as that of our clients. Because we are driven by the same ambition as our clients: to dare to be the best!
Horlings not only has many life science companies as a tax and/or accountancy client, we also have a proven track record in arranging the new Dutch Innovation Box regime for many of these clients. Because Horlings knows the business like no other, we are able to cooperate swift and (cost-)efficient.

Science and Technologies or Services

Review or audit of (consolidated) accounts, IFRS and US Gaap knowledge, Valuations, VAT advice and VAT compliance (Dutch and EU), Corporate income tax advice and return, M&A, transfer pricing, rulings, Tax litigation (all courts), Payroll, Transaction services, IT Audit.

Alliances

Together with Koenen en Co and KroesWevers we form the alliance Nexia Nederland, one of the 10 largest accountants and consulting firms of the Netherlands with approximately 700 professionals. The member firms are independent and combine the benefits of a larger as well as a smaller organisation.
Nexia Nederland is member of Nexia International, a network of independent accountants and consulting firms with 620 offices in 97 countries. Nexia International is one of the worlds’ largest networks of professional services.

Keywords

Tax, Account, Payroll, VAT, Audit, Expat, Amsterdam, Finance, Service

3 Laurence Poutney Hill
EC4R 0EU London
Website
E-mail
T +44 (0)207 002 0000

Employees: 200
Employees in R&D: 200
Year of foundation: 1998

Company Profile

• Hydrogen is an AIM listed company with a £160m turnover since founding the business in 1998.
• We have placed candidates in over 40 countries globally.
• We have a balanced business 50% contract and 50% permanent across professional, technical & scientific services.
• We employ approximately 400 staff globally with offices in Singapore, Hong Kong, Sydney, Edinburgh and London and planned offices for Europe, Houston and Norway
• Using our dedicated research teams across the globe, we pride ourselves on having relationships with the best candidates and being able to offer our clients access to specialist candidates they typically cannot find themselves.

Science and Technologies or Services

• Hydrogen Group has over 250 Clinical & Regulatory freelancers currently working across 48 out of 50 countries in Europe.
• We focus on constantly maintaining networks of the top 20% of (often passive) candidates within each region in order to respond to requests the quickest.
• We work to your budget and offer an all inclusive service with 24 hour CV turnaround after receiving a job specification, so are well equipped to deal with urgent needs.
• We only work with candidates that come to us by personal recommendations and referrals gained by face-to-face networking on the ground in each region – Many of our candidates work with Hydrogen on an exclusive basis and therefore you will not get access to them through other suppliers or your own networks.
• Our core regions are: Benelux, Scandinavia, France, Spain, Italy, Germany / Austria, Poland, Hungary, Czech / Slovakia.
• We are also actively maintaining candidate networks in: UK, the Baltics, former Yugoslavia, Romania, Greece, Ukraine, Russia, and Turkey.

Alliances

CRO's, Pharmaceutical, Biotech and Medical Device Companies

Keywords

Clinical, Resourcing, Specialist, CRA, CPM, Freelance, Permanent, Regulatory Affairs, CRO, Recruitment